@article{DanyszDekundyScheschonkaetal.2021,
  author    = {Danysz, Wojciech and Dekundy, Andrzej and Scheschonka, Astrid and Riederer, Peter},
  title     = {Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials},
  series = {Journal of Neural Transmission},
  volume    = {128},
  journal   = {Journal of Neural Transmission},
  number    = {2},
  doi       = {10.1007/s00702-021-02306-2},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-330133},
  pages     = {127-169},
  year      = {2021},
  abstract  = {The aim of the current review was to provide a new, in-depth insight into possible pharmacological targets of amantadine to pave the way to extending its therapeutic use to further indications beyond Parkinson's disease symptoms and viral infections. Considering amantadine's affinities in vitro and the expected concentration at targets at therapeutic doses in humans, the following primary targets seem to be most plausible: aromatic amino acids decarboxylase, glial-cell derived neurotrophic factor, sigma-1 receptors, phosphodiesterases, and nicotinic receptors. Further three targets could play a role to a lesser extent: NMDA receptors, 5-HT3 receptors, and potassium channels. Based on published clinical studies, traumatic brain injury, fatigue [e.g., in multiple sclerosis (MS)], and chorea in Huntington's disease should be regarded potential, encouraging indications. Preclinical investigations suggest amantadine's therapeutic potential in several further indications such as: depression, recovery after spinal cord injury, neuroprotection in MS, and cutaneous pain. Query in the database http://www.clinicaltrials.gov reveals research interest in several further indications: cancer, autism, cocaine abuse, MS, diabetes, attention deficit-hyperactivity disorder, obesity, and schizophrenia.},
  language  = {en}
}
@article{NauePfeiferAugustinetal.2021,
  author    = {Naue, Jana and Pfeifer, Manuel and Augustin, Christa and Becker, Julia and Fleckhaus, Jan and Grabm{\"u}ller, Melanie and Han, Yang and Heidorn, Frank and Hollaender, Olivia and Klein-Unseld, Rachel and Kulstein, Galina and Lichtenwald, Julia and Neubauer, Jacqueline and Suarez, Philippe and Haas, Cordula and Schneider, Peter M. and Vennemann, Marielle and B{\"o}hme, Petra},
  title     = {Forensische DNA-Methylierungsanalyse},
  series = {Rechtsmedizin},
  volume    = {31},
  journal   = {Rechtsmedizin},
  number    = {3},
  organization    = {Arbeitsgemeinschaft Molekulare Alterssch{\"a}tzung der Deutschen Gesellschaft f{\"u}r Rechtsmedizin (DGRM)},
  issn      = {0937-9819},
  doi       = {10.1007/s00194-021-00493-6},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-307129},
  pages     = {202-216},
  year      = {2021},
  abstract  = {Mit der Entdeckung altersabh{\"a}ngiger epigenetischer Ver{\"a}nderungen, der DNA-Methylierung (DNAm), hat sich eine neue M{\"o}glichkeit aufgezeigt, das Alter eines Individuums zu sch{\"a}tzen. Die Methode wurde intensiv erforscht und ihre Anwendung in der forensischen Fallarbeit durch die Aktualisierung des \S 81e der Strafprozessordnung (StPO) in Deutschland reguliert. Zur Untersuchung des DNAm-Grades m{\"u}ssen neue Techniken etabliert und validiert werden. Dies macht die Pr{\"u}fung der Vergleichbarkeit von Messergebnissen aus verschiedenen forensischen Laboren erforderlich. Hierzu f{\"u}hrte die Arbeitsgruppe „Molekulare Alterssch{\"a}tzung" der Deutschen Gesellschaft f{\"u}r Rechtsmedizin (DGRM) im Winter 2019/2020 den 2. Ringversuch (RV) zur quantitativen DNAm-Analyse mithilfe der Mini- und der Pyrosequenzierung durch. Dieser basierte auf den Erfahrungen des 1. RV 2018/2019, dessen Ergebnisse in dieser Ausgabe ebenfalls vorgestellt werden. Die aktuelle Studie umfasst Analyseergebnisse aus 12 Laboren (ingesamt 14 teilnehmende Labore), von denen einige beide Methoden angewandt haben. Zus{\"a}tzlich f{\"u}hrten 4 Labore eine Alterssch{\"a}tzung an den RV-Proben mit eigenen Markerkombinationen und Modellen durch. Da diese auf unterschiedlichen Referenzdaten und Markerkombinationen beruhen, erfolgte kein qualitativer Vergleich der Modelle, sondern das grunds{\"a}tzliche Potenzial der Methodik wurde verdeutlicht. Ziele des RV waren die Evaluierung der Vergleichbarkeit der DNAm-Messungen und die Bewertung m{\"o}glicher Einflussfaktoren, wie Extraktionsmethode und verwendetes Ger{\"a}t. Die Ergebnisse zeigen, dass sich die gemessenen DNAm-Werte der untersuchten Marker sowohl zwischen Mini- und Pyrosequenzierung als auch innerhalb der jeweiligen Methode zwischen den Laboren unterscheiden k{\"o}nnen, sodass mit Schwankungen gerechnet werden muss.},
  language  = {de}
}
@article{PotreckMutkeWeylandetal.2021,
  author    = {Potreck, Arne and Mutke, Matthias A. and Weyland, Charlotte S. and Pfaff, Johannes A. R. and Ringleb, Peter A. and Mundiyanapurath, Sibu and M{\"o}hlenbruch, Markus A. and Heiland, Sabine and Pham, Mirko and Bendszus, Martin and Hoffmann, Angelika},
  title     = {Combined Perfusion and Permeability Imaging Reveals Different Pathophysiologic Tissue Responses After Successful Thrombectomy},
  series = {Translational Stroke Research},
  volume    = {12},
  journal   = {Translational Stroke Research},
  number    = {5},
  issn      = {1868-4483},
  doi       = {10.1007/s12975-020-00885-y},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-308946},
  pages     = {799-807},
  year      = {2021},
  abstract  = {Despite successful recanalization of large-vessel occlusions in acute ischemic stroke, individual patients profit to a varying degree. Dynamic susceptibility-weighted perfusion and dynamic T1-weighted contrast-enhanced blood-brain barrier permeability imaging may help to determine secondary stroke injury and predict clinical outcome. We prospectively performed perfusion and permeability imaging in 38 patients within 24 h after successful mechanical thrombectomy of an occlusion of the middle cerebral artery M1 segment. Perfusion alterations were evaluated on cerebral blood flow maps, blood-brain barrier disruption (BBBD) visually and quantitatively on ktrans maps and hemorrhagic transformation on susceptibility-weighted images. Visual BBBD within the DWI lesion corresponded to a median ktrans elevation (IQR) of 0.77 (0.41-1.4) min-1 and was found in all 7 cases of hypoperfusion (100\%), in 10 of 16 cases of hyperperfusion (63\%), and in only three of 13 cases with unaffected perfusion (23\%). BBBD was significantly associated with hemorrhagic transformation (p < 0.001). While BBBD alone was not a predictor of clinical outcome at 3 months (positive predictive value (PPV) = 0.8 [0.56-0.94]), hypoperfusion occurred more often in patients with unfavorable clinical outcome (PPV = 0.43 [0.10-0.82]) compared to hyperperfusion (PPV = 0.93 [0.68-1.0]) or unaffected perfusion (PPV = 1.0 [0.75-1.0]). We show that combined perfusion and permeability imaging reveals distinct infarct signatures after recanalization, indicating the severity of prior ischemic damage. It assists in predicting clinical outcome and may identify patients at risk of stroke progression.},
  language  = {en}
}